Literature DB >> 20457787

Enterotoxigenic Escherichia coli elicits immune responses to multiple surface proteins.

Koushik Roy1, Scott Bartels, Firdausi Qadri, James M Fleckenstein.   

Abstract

Enterotoxigenic Escherichia coli (ETEC) causes considerable morbidity and mortality due to diarrheal illness in developing countries, particularly in young children. Despite the global importance of these heterogeneous pathogens, a broadly protective vaccine is not yet available. While much is known regarding the immunology of well-characterized virulence proteins, in particular the heat-labile toxin (LT) and colonization factors (CFs), to date, evaluation of the immune response to other antigens has been limited. However, the availability of genomic DNA sequences for ETEC strains coupled with proteomics technology affords opportunities to examine novel uncharacterized antigens that might also serve as targets for vaccine development. Analysis of whole or fractionated bacterial proteomes with convalescent-phase sera can potentially accelerate identification of secreted or surface-expressed targets that are recognized during the course of infection. Here we report results of an immunoproteomics approach to antigen discovery with ETEC strain H10407. Immunoblotting of proteins separated by two-dimensional electrophoresis (2DE) with sera from mice infected with strain H10407 or with convalescent human sera obtained following natural ETEC infections demonstrated multiple immunoreactive molecules in culture supernatant, outer membrane, and outer membrane vesicle preparations, suggesting that many antigens are recognized during the course of infection. Proteins identified by this approach included established virulence determinants, more recently identified putative virulence factors, as well as novel secreted and outer membrane proteins. Together, these studies suggest that existing and emerging proteomics technologies can provide a useful complement to ongoing approaches to ETEC vaccine development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457787      PMCID: PMC2897383          DOI: 10.1128/IAI.00264-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  64 in total

1.  Phenotypic diversity of enterotoxigenic Escherichia coli strains from a community-based study of pediatric diarrhea in periurban Egypt.

Authors:  L F Peruski; B A Kay; R A El-Yazeed; S H El-Etr; A Cravioto; T F Wierzba; M Rao; N El-Ghorab; H Shaheen; S B Khalil; K Kamal; M O Wasfy; A M Svennerholm; J D Clemens; S J Savarino
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

2.  The pCoo plasmid of enterotoxigenic Escherichia coli is a mosaic cointegrate.

Authors:  Barbara Froehlich; Julian Parkhill; Mandy Sanders; Michael A Quail; June R Scott
Journal:  J Bacteriol       Date:  2005-09       Impact factor: 3.490

3.  Serologic proteome analysis of Borrelia burgdorferi membrane-associated proteins.

Authors:  Andrew J Nowalk; Robert D Gilmore; James A Carroll
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Surface analyses and immune reactivities of major cell wall-associated proteins of group a streptococcus.

Authors:  Jason N Cole; Ruben D Ramirez; Bart J Currie; Stuart J Cordwell; Steven P Djordjevic; Mark J Walker
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

Review 5.  Vaccines for enterotoxigenic Escherichia coli: current status.

Authors:  Edgar C Boedeker
Journal:  Curr Opin Gastroenterol       Date:  2005-01       Impact factor: 3.287

6.  Identification of a glycoprotein produced by enterotoxigenic Escherichia coli.

Authors:  C Lindenthal; E A Elsinghorst
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

Review 7.  Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention.

Authors:  Firdausi Qadri; Ann-Mari Svennerholm; A S G Faruque; R Bradley Sack
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

8.  Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery.

Authors:  D Huw Davies; Xiaowu Liang; Jenny E Hernandez; Arlo Randall; Siddiqua Hirst; Yunxiang Mu; Kimberly M Romero; Toai T Nguyen; Mina Kalantari-Dehaghi; Shane Crotty; Pierre Baldi; Luis P Villarreal; Philip L Felgner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

9.  Identification of a two-partner secretion locus of enterotoxigenic Escherichia coli.

Authors:  James M Fleckenstein; Koushik Roy; Julia F Fischer; Michael Burkitt
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

10.  Importance of heat-labile enterotoxin in colonization of the adult mouse small intestine by human enterotoxigenic Escherichia coli strains.

Authors:  Kenneth P Allen; Mildred M Randolph; James M Fleckenstein
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

View more
  35 in total

1.  A comparative genomic analysis of diverse clonal types of enterotoxigenic Escherichia coli reveals pathovar-specific conservation.

Authors:  Jason W Sahl; Hans Steinsland; Julia C Redman; Samuel V Angiuoli; James P Nataro; Halvor Sommerfelt; David A Rasko
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

Review 2.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Transcriptional modulation of enterotoxigenic Escherichia coli virulence genes in response to epithelial cell interactions.

Authors:  Rita Kansal; David A Rasko; Jason W Sahl; George P Munson; Koushik Roy; Qingwei Luo; Alaullah Sheikh; Kurt J Kuhne; James M Fleckenstein
Journal:  Infect Immun       Date:  2012-10-31       Impact factor: 3.441

4.  EatA, an immunogenic protective antigen of enterotoxigenic Escherichia coli, degrades intestinal mucin.

Authors:  Pardeep Kumar; Qingwei Luo; Tim J Vickers; Alaullah Sheikh; Warren G Lewis; James M Fleckenstein
Journal:  Infect Immun       Date:  2013-11-11       Impact factor: 3.441

5.  Analysis of global transcriptional profiles of enterotoxigenic Escherichia coli isolate E24377A.

Authors:  Jason W Sahl; David A Rasko
Journal:  Infect Immun       Date:  2012-01-03       Impact factor: 3.441

6.  Use of a Novel Report Protein to Study the Secretion Signal of Flagellin in Bacillus subtilis.

Authors:  Guangqiang Wang; Yongjun Xia; Zhiqiang Xiong; Hui Zhang; Lianzhong Ai
Journal:  Curr Microbiol       Date:  2016-05-06       Impact factor: 2.188

7.  Human Experimental Challenge With Enterotoxigenic Escherichia coli Elicits Immune Responses to Canonical and Novel Antigens Relevant to Vaccine Development.

Authors:  Subhra Chakraborty; Arlo Randall; Tim J Vickers; Doug Molina; Clayton D Harro; Barbara DeNearing; Jessica Brubaker; David A Sack; A Louis Bourgeois; Philip L Felgner; Xiaowu Liang; Sachin Mani; Heather Wenzel; R Reid Townsend; Petra E Gilmore; Michael J Darsley; David A Rasko; James M Fleckenstein
Journal:  J Infect Dis       Date:  2018-09-22       Impact factor: 5.226

Review 8.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

9.  Enterotoxigenic Escherichia coli: Orchestrated host engagement.

Authors:  James M Fleckenstein; George M Munson; David A Rasko
Journal:  Gut Microbes       Date:  2013-07-25

10.  Enterotoxigenic Escherichia coli secretes a highly conserved mucin-degrading metalloprotease to effectively engage intestinal epithelial cells.

Authors:  Qingwei Luo; Pardeep Kumar; Tim J Vickers; Alaullah Sheikh; Warren G Lewis; David A Rasko; Jeticia Sistrunk; James M Fleckenstein
Journal:  Infect Immun       Date:  2013-11-18       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.